Moleculin Biotech Nears Pivotal Trial Unblinding, Reports Strong Blinded Efficacy Data for Annamycin
MBRX sits 38% above its 52-week low of $1.79.
Summary
Moleculin Biotech announced it is approaching the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin, reporting preliminary blinded efficacy data showing a 30% complete remission rate, significantly outperforming historical benchmarks.
Key Events · Product Development and Regulatory · MBRX
-
Imminent Trial Unblinding
The company is approaching the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML), expected before June 30, 2026.
-
Strong Preliminary Efficacy Data
Preliminary blinded data for the first 45 subjects show a complete remission (CR) rate of approximately 30% and a composite complete remission rate (CRc) exceeding 40%.
-
Significant Improvement Over Standard of Care
The 30% CR rate represents a ~67% improvement compared to historical CR rates of 17-18% for cytarabine alone in similar patient populations.
-
Trial Progress
56 out of 90 subjects (62%) have been recruited for Part A of the trial, keeping the company on track to complete recruitment in Q3 2026.
Analysis · MBRX · Life Sciences
This 8-K provides a crucial update on Moleculin's lead drug candidate, Annamycin, in its pivotal MIRACLE trial. The reported preliminary blinded efficacy data, showing a 30% complete remission rate, is a substantial improvement over current standard-of-care treatments for relapsed or refractory AML. The imminent unblinding of this data before June 30, 2026, is a major near-term catalyst that could significantly impact the company's valuation and its ability to secure the "significant additional financing" it needs, as highlighted in the forward-looking statements. Positive unblinded results would de-risk the program and provide a much-needed boost for a company that recently issued a going concern warning.
At the time of this filing, MBRX was trading at $2.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $1.79 to $28.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.